Survival comparison between recipients of the self-design biological and commercial mitral valve in the National Cardiology Institute of Mexico

Background: Objective: In this paper, we present our 4-year experience (2015-2019) using a mitral valve prosthesis manufactured by the National Institute of Cardiology of Mexico and compare its use and clinical impact to other commercial-type prostheses. Methods: One hundred and ten patients underwent open mitral valve replacement, 55% received a mechanical mitral valve replacement, Sorin Carbomedics (SC) was used in 8 patients, and ST. Jude (SJ) in 53 patients. On the other hand, 45% of patients received biological mitral valve, ST. Jude (SJB) in 7 patients, Carpenter Edwards (CE) in 4 patients, and 38 received biological mitral valve replacement of the INC. Results: Postoperative follow-up revealed that the main complications presented were bacterial growth in those patients with SC (25%) and SJ (15%) valves and the need for dialysis in patients with CS (25%) and SJ (13.2%). Interestingly, patients with INC self-designed valves have the fewest cases of bacterial growth (13.1%) and need dialysis (10.5%). During the following six years, the mortality of patients treated with a BJS valve was 28.5%, INC 18.4%, SJ 15%, SC 12.5%, and CE 0%. Conclusion: These results show that the quality of the INC self-designed biological valve is similar to that of commercial valves, providing patients with improved quality of life and life expectancy at a low cost.